Article

The Benefits of Jakafi for Patients With PV

Patients with PV tend to be very symptomatic, but Jakafi can help.

Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) — a type of myeloproliferative neoplasm.

Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of bald man.
Image of man.
Image of Kumar.
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Related Content